{{item.videoDuration}}
{{item.title}}
{{item.text}}
{{item.videoDuration}}
{{item.title}}
{{item.text}}
A team of PwC Switzerland led by Martin James and Luca Borrelli acted as financial and tax advisor to Neuraxpharm in the acquisition of Easypharm.
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, announced the expansion of its operations in Central Europe with the launch of Neuraxpharm Austria, and the acquisition of Easypharm OTC GmbH, a privately-owned Austrian Consumer Healthcare company.
Neuraxpharm develops and commercialises value added medicines, standard generics and Consumer Healthcare products, e.g. probiotics and other nutraceuticals in Europe. Neuraxpharm's mission is to offer a wide range of proven, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners – based on our in-depth knowledge of the diverse CNS markets in the European countries.
Easypharm focuses purely on Consumer Healthcare via, among others, its two leading CNS brands, easysleep® and easyrelax®. easypharm currently sells and distributes in Austria with its own highly experienced sales force company Frank & Co, covering more than 70% of Austrian pharmacies.
